KemPharm

$10.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.42 (+4.36%) Today
+$0.05 (+0.50%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell KemPharm and other stocks, options, and ETFs commission-free!

About KMPH

KemPharm, Inc. Common Stock, also called KemPharm, is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA. The listed name for KMPH is KemPharm, Inc. Common Stock.

CEO
Travis C. Mickle
Employees
22
Headquarters
Celebration, Florida
Founded
2006
Market Cap
264.98M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
10.23M
High Today
$10.43
Low Today
$8.21
Open Price
$10.43
Volume
5.23M
52 Week High
$18.15
52 Week Low
$5.86

KMPH News

BenzingaMar 3

Mid-Day Market Update: Crude Oil Surges 3%; KemPharm Shares Spike Higher

Midway through trading Wednesday, the Dow traded up 0.26% to 31,472 while the NASDAQ fell 1.02% to 13,222.06. The S&P also fell, dropping 0.30% to 3,858.49. Th
BenzingaMar 3

Why Is It Moving? Analyzing The Upward Movement in KemPharm's Stock Today

The Price And Volume Action In KemPharm's Stock Today KemPharm's (NASDAQ:KMPH) stock is trading up 46.23% to a price of $14.92. Wednesday the stock has been tr
BenzingaMar 3

The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 2) Bioanalyti

KMPH Earnings

-$0.46
-$0.29
-$0.11
$0.06
Q4 FY18
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
— per share
Actual
Expected Nov 12, After Hours
Replay Earnings Call

You May Also Like

SFBS

More KMPH News

BenzingaFeb 28

Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates

Most Food and Drug Administration decisions scheduled for February were positive, and more importantly five new molecular entities passed FDA muster. NME appro
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure